Phase I Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs Venetoclax (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms V+DA-EPOCH-R
- 25 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 25 Mar 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Aug 2019.
- 18 May 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.